Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 328.9 Million USD | -6.51% |
| 2022 | 351.8 Million USD | 0.29% |
| 2021 | 350.8 Million USD | 14.27% |
| 2020 | 307 Million USD | 37.98% |
| 2019 | 222.5 Million USD | 8.11% |
| 2018 | 205.8 Million USD | 44.11% |
| 2017 | 142.81 Million USD | 92.98% |
| 2016 | 74 Million USD | -3.81% |
| 2015 | 76.93 Million USD | 17.15% |
| 2014 | 65.67 Million USD | 348.5% |
| 2013 | 14.64 Million USD | -3.42% |
| 2012 | 15.16 Million USD | 3.41% |
| 2011 | 14.66 Million USD | 15.24% |
| 2010 | 12.72 Million USD | -5.91% |
| 2009 | 13.52 Million USD | -31.46% |
| 2008 | 19.72 Million USD | 16.75% |
| 2007 | 16.89 Million USD | -31.65% |
| 2006 | 24.72 Million USD | 50.36% |
| 2005 | 16.44 Million USD | 24.05% |
| 2004 | 13.25 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 307 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 317.5 Million USD | -4.77% |
| 2024 Q1 | 333.4 Million USD | 1.37% |
| 2023 Q1 | 367.9 Million USD | 4.58% |
| 2023 Q3 | 354.1 Million USD | -0.06% |
| 2023 Q2 | 354.3 Million USD | -3.7% |
| 2023 FY | 328.9 Million USD | -6.51% |
| 2023 Q4 | 328.9 Million USD | -7.12% |
| 2022 FY | 351.8 Million USD | 0.29% |
| 2022 Q2 | 425.5 Million USD | 6.19% |
| 2022 Q1 | 400.7 Million USD | 14.22% |
| 2022 Q3 | 546.3 Million USD | 28.39% |
| 2022 Q4 | 351.8 Million USD | -35.6% |
| 2021 Q2 | 386.4 Million USD | -4.94% |
| 2021 Q1 | 406.5 Million USD | 32.41% |
| 2021 Q4 | 350.8 Million USD | -3.78% |
| 2021 Q3 | 364.6 Million USD | -5.64% |
| 2021 FY | 350.8 Million USD | 14.27% |
| 2020 Q4 | 307 Million USD | 13.66% |
| 2020 FY | 307 Million USD | 37.98% |
| 2020 Q1 | 248.1 Million USD | 11.51% |
| 2020 Q2 | 236.2 Million USD | -4.8% |
| 2020 Q3 | 270.1 Million USD | 14.35% |
| 2019 Q2 | 232 Million USD | 9.95% |
| 2019 Q1 | 211 Million USD | 2.53% |
| 2019 FY | 222.5 Million USD | 8.11% |
| 2019 Q3 | 230.2 Million USD | -0.78% |
| 2019 Q4 | 222.5 Million USD | -3.34% |
| 2018 FY | 205.8 Million USD | 44.11% |
| 2018 Q1 | 155.19 Million USD | 8.67% |
| 2018 Q2 | 139.37 Million USD | -10.2% |
| 2018 Q4 | 205.8 Million USD | 63.66% |
| 2018 Q3 | 125.74 Million USD | -9.78% |
| 2017 Q4 | 142.81 Million USD | 107.31% |
| 2017 Q2 | 70.52 Million USD | -0.29% |
| 2017 FY | 142.81 Million USD | 92.98% |
| 2017 Q1 | 70.73 Million USD | -4.42% |
| 2017 Q3 | 68.88 Million USD | -2.33% |
| 2016 Q3 | 81.16 Million USD | -16.05% |
| 2016 FY | 74 Million USD | -3.81% |
| 2016 Q4 | 74 Million USD | -8.82% |
| 2016 Q2 | 96.67 Million USD | 9.61% |
| 2016 Q1 | 88.2 Million USD | 14.64% |
| 2015 Q4 | 76.93 Million USD | -3.91% |
| 2015 Q2 | 84.7 Million USD | 3.13% |
| 2015 Q1 | 82.13 Million USD | 25.06% |
| 2015 FY | 76.93 Million USD | 17.15% |
| 2015 Q3 | 80.07 Million USD | -5.48% |
| 2014 Q2 | 66.03 Million USD | -7.35% |
| 2014 FY | 65.67 Million USD | 348.5% |
| 2014 Q3 | 62.53 Million USD | -5.3% |
| 2014 Q1 | 71.26 Million USD | 386.7% |
| 2014 Q4 | 65.67 Million USD | 5.02% |
| 2013 Q1 | 22.14 Million USD | 46.09% |
| 2013 Q3 | 16.32 Million USD | -12.15% |
| 2013 Q2 | 18.58 Million USD | -16.1% |
| 2013 Q4 | 14.64 Million USD | -10.3% |
| 2013 FY | 14.64 Million USD | -3.42% |
| 2012 FY | 15.16 Million USD | 3.41% |
| 2012 Q2 | 16 Million USD | -7.57% |
| 2012 Q3 | 18.24 Million USD | 13.97% |
| 2012 Q4 | 15.16 Million USD | -16.9% |
| 2012 Q1 | 17.31 Million USD | 18.13% |
| 2011 Q2 | 17.26 Million USD | -22.11% |
| 2011 FY | 14.66 Million USD | 15.24% |
| 2011 Q1 | 22.16 Million USD | 74.21% |
| 2011 Q3 | 17.97 Million USD | 4.15% |
| 2011 Q4 | 14.66 Million USD | -18.45% |
| 2010 FY | 12.72 Million USD | -5.91% |
| 2010 Q2 | 17.11 Million USD | 0.2% |
| 2010 Q1 | 17.08 Million USD | 26.33% |
| 2010 Q4 | 12.72 Million USD | -26.55% |
| 2010 Q3 | 17.32 Million USD | 1.19% |
| 2009 Q1 | 14.15 Million USD | -28.26% |
| 2009 Q4 | 13.52 Million USD | -14.51% |
| 2009 FY | 13.52 Million USD | -31.46% |
| 2009 Q3 | 15.81 Million USD | 12.63% |
| 2009 Q2 | 14.04 Million USD | -0.78% |
| 2008 Q3 | 17.51 Million USD | -7.22% |
| 2008 Q2 | 18.87 Million USD | 0.47% |
| 2008 Q1 | 18.79 Million USD | 11.2% |
| 2008 FY | 19.72 Million USD | 16.75% |
| 2008 Q4 | 19.72 Million USD | 12.63% |
| 2007 Q4 | 16.89 Million USD | -34.06% |
| 2007 FY | 16.89 Million USD | -31.65% |
| 2007 Q2 | 28.88 Million USD | 7.44% |
| 2007 Q1 | 26.88 Million USD | 8.75% |
| 2007 Q3 | 25.62 Million USD | -11.29% |
| 2006 FY | 24.72 Million USD | 50.36% |
| 2006 Q4 | 24.72 Million USD | -11.92% |
| 2006 Q3 | 28.06 Million USD | 0.0% |
| 2005 Q4 | 16.44 Million USD | 0.0% |
| 2005 FY | 16.44 Million USD | 24.05% |
| 2004 FY | 13.25 Million USD | 0.0% |
| 2004 Q4 | 13.25 Million USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2001 Q4 | 350.8 Million USD | 0.0% |
| 2001 FY | 307 Million USD | 0.0% |
| 2000 Q4 | 351.8 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 581.38 Million USD | 43.428% |
| Bausch Health Companies Inc. | 1.54 Billion USD | 78.698% |
| Catalent, Inc. | 574 Million USD | 42.7% |
| Elanco Animal Health Incorporated | 1.73 Billion USD | 81.043% |
| Perrigo Company plc | 1.14 Billion USD | 71.172% |
| Teva Pharmaceutical Industries Limited | 4.02 Billion USD | 91.82% |
| Zoetis Inc. | 2.56 Billion USD | 87.172% |